Target intelligence / Profile preview

Ribosomal protein L24 (RPL24)

Target
RPL24
Molecular classification
Ribosomal protein, Structural protein (component of 60S ribosomal subunit), L24E family
01

Overview

Ribosomal protein L24 (RPL24) is a structural component of the large (60S) ribosomal subunit, belonging to the L24E family of ribosomal proteins and located in the cytoplasm[1][2][4]. RPL24 is essential for protein synthesis by facilitating ribosome assembly and function. Beyond its classic ribosomal role, RPL24 modulates cap-dependent mRNA translation—overexpression in various cancers supports tumorigenesis via sustained protein production critical for cell survival and proliferation, while loss impairs 80S ribosome formation, reduces cell viability, and diminishes tumor cell growth[1]. RPL24 is also implicated in microRNA biogenesis through its interaction with components like DDX5, affecting the maturation of specific miR precursors[1]. Disease relevance includes a role in multiple cancers (breast, liver, laryngeal) and an association with immunodeficiency syndromes[2][3]. RPL24 has been explored experimentally as a potential therapeutic target, particularly for cancer, but there are no known direct small molecule or biologic drugs currently targeting it in clinical practice[1][3].

Other names
60S ribosomal protein L24Large ribosomal subunit protein eL24L24eL24ribosomal protein L3060S ribosomal protein L30HEL-S-310epididymis secretory protein Li 310
02

Biological functions

Protein synthesis (translation)Ribosome assemblyRegulation of cap-dependent mRNA translationRegulation of microRNA (miRNA) processing/biogenesis
03

Disease associations

Cancer (notably breast cancer, liver cancer, laryngeal carcinoma)Immunodeficiency (Immunodeficiency 60)
04

Safety considerations

Possible concerns regarding global translation inhibition, but no clinical safety data available
05

Biomarkers

Potential cancer biomarker (based on overexpression/acetylation in cancer)

Beyond the preview

Go deeper on Ribosomal protein L24 (RPL24).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L24 (RPL24).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call